BioAge公布BGE-102一期临床新数据:脑渗透NLRP3抑制剂展现卓越降HSCRP潜力

投资观察
Yesterday

BioAge Labs Inc. 最新发布其候选药物BGE-102的一期临床试验补充积极中期数据。该药物作为一种创新型脑渗透性NLRP3抑制剂,在心血管风险升高受试者中表现出降低超敏C反应蛋白的同类最佳潜力。

试验结果显示,BGE-102耐受性良好,安全性特征优异。公司预计将于2026年上半年获得完整一期临床数据,并计划同期启动二期A阶段研究。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10